KalVista Pharmaceuticals Inc KALV Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$27.00 unchanged at close Jun 12
Last close · Previous close $27.00
- Market cap
- At the Jun 12 close
- Dividend yield
- NoneLast 12 months
Price chart
$27.00unchangedFri, Jun 12 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$27.00Jun 11
- Volume0.00Jun 12 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.09MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $10.55 to $27.00; now $27.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Jun 12 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
KALV beat the S&P 500 in all 3 periods compared.
| Period | KALV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | KALV: up 1.0% S&P 500: up 0.5% | KALV beat the S&P 500 by 0.5 percentage points Beat |
| 3M | KALV: up 55.4% S&P 500: up 11.7% | KALV beat the S&P 500 by 43.7 percentage points Beat |
| YTD | KALV: up 67.2% S&P 500: up 9.1% | KALV beat the S&P 500 by 58.1 percentage points Beat |
| 1Y | KALV: up 106.3% S&P 500: — | No S&P 500 comparison for this period |
| Long term | ||
| 3Y | KALV: up 179.8% S&P 500: — +40.9% vs — a year | No S&P 500 comparison for this period |
| 5Y | KALV: down 6.1% S&P 500: — −1.2% vs — a year | No S&P 500 comparison for this period |
| 10Y | KALV: up 70.7% S&P 500: — +5.5% vs — a year | No S&P 500 comparison for this period |
$10,000 invested in KALV 10 years ago (Jun 10, 2016) would be worth about $17,067 at the close on , with dividends reinvested.
KALV beat the S&P 500 in all 3 periods compared.
| Period | KALV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | KALV: up 1.0% S&P 500: up 0.5% | KALV beat the S&P 500 by 0.5 percentage points Beat |
| 3M | KALV: up 55.4% S&P 500: up 11.4% | KALV beat the S&P 500 by 44.0 percentage points Beat |
| YTD | KALV: up 67.2% S&P 500: up 8.8% | KALV beat the S&P 500 by 58.4 percentage points Beat |
| 1Y | KALV: up 106.3% S&P 500: — | No S&P 500 comparison for this period |
| Long term | ||
| 3Y | KALV: up 179.8% S&P 500: — +40.9% vs — a year | No S&P 500 comparison for this period |
| 5Y | KALV: down 6.1% S&P 500: — −1.2% vs — a year | No S&P 500 comparison for this period |
| 10Y | KALV: up 70.7% S&P 500: — +5.5% vs — a year | No S&P 500 comparison for this period |
$10,000 invested in KALV 10 years ago (Jun 10, 2016) would be worth about $17,067 at the close on , not counting dividends.
All-time high
$126.56
Closing high on . Now 78.7% below that record.
Split-adjusted daily closes since Apr 9, 2015.
Stock splits
1
1-for-14 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY26, the quarter ended Mar 31, 2026, and balance-sheet figures are as of Mar 31, 2026. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Apr 30, 2024) | $0.00 | −$44.65M | −$1.07 |
| Q1 FY25 (Sep 30, 2024) | $0.00 | −$39.08M | −$0.84 |
| Q2 FY25 (Dec 31, 2024) | Not reported | Not reported | Not reported |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$51.84M | −$0.98 |
| Q2 FY25 (Jul 31, 2025) | $1.43M | −$60.10M | −$1.12 |
| Q3 FY25 (Sep 30, 2025) | $13.69M | −$49.48M | −$0.92 |
| Q4 FY25 (Dec 31, 2025) | Not reported | Not reported | Not reported |
| Q1 FY26 (Mar 31, 2026) | $40.86M | −$23.49M | −$0.43 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Apr 30, 2021) | $0.00 | −$46.24M | −$2.42 |
| FY22 (Apr 30, 2022) | $0.00 | −$82.34M | −$3.36 |
| FY23 (Apr 30, 2023) | $0.00 | −$92.91M | −$3.33 |
| FY24 (Dec 31, 2024) | Not reported | Not reported | Not reported |
| FY25 (Dec 31, 2025) | Not reported | Not reported | Not reported |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $285.03MAs of Mar 31, 2026
Cash plus short- and long-term marketable securities on the Mar 31, 2026 balance sheet.
- Total debt$149.81MAs of Mar 31, 2026
- Net cash$135.22MAs of Mar 31, 2026
- 5.17As of Mar 31, 2026
Current assets divided by current liabilities on the Mar 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY ®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
KALV news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
KALV stock FAQ
What is KALV stock’s price today?
KalVista Pharmaceuticals (KALV) traded at $27.00 at the close on , unchanged from the previous close of $27.00. Over the past 52 weeks it has traded between $10.55 and $27.00.
If you invested $1,000 in KALV 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in KALV on would be worth about $1,707 at the close on , a total return of +70.7%. The same $1,000 would be worth $939 if invested five years ago and $2,063 if invested one year ago. Past performance doesn’t predict future returns.
Does KALV pay a dividend?
KalVista Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is KALV’s 52-week high and low?
Over the past 52 weeks KALV has traded as low as $10.55 and as high as $27.00. At $27.00 at the close on , it is 0.0% below that high and 155.9% above the low.
What is KALV’s all-time high?
KALV’s highest closing price was $126.56 on , adjusted for stock splits. At $27.00 at the close on , it is 78.7% below that record.
Has KALV stock ever split?
Yes, once: 1-for-14 on .
How has KALV stock performed?
Including dividends and measured to the close on , KALV has returned +67.2% so far this year and +106.3% over the past year, and −6.1% over five years (−1.2% a year). Past performance doesn’t predict future returns.
What sector and industry is KalVista Pharmaceuticals in?
KalVista Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does KALV trade on?
KalVista Pharmaceuticals trades on the Nasdaq under the ticker symbol KALV. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.